New research spearheaded by geneticists and clinicians at the Seaver Autism Center for Research and Treatment at Mount Sinai has fundamentally shifted our understanding of Phelan-McDermid syndrome (PMS), a rare and complex genetic disorder. Published in the peer-reviewed journal Autism Research, the landmark study estimates that the condition affects approximately 1 in every 7,300 individuals. This figure represents a dramatic departure from earlier, more conservative epidemiological estimates, suggesting that tens of thousands of people across the United States and globally may be living with the condition without ever receiving an accurate clinical diagnosis. <\/p>\n
The findings arrive at a critical juncture in neurodevelopmental research. As targeted, precision-medicine therapeutics advance through clinical pipelines, the imperative to identify undiagnosed individuals has transitioned from a purely diagnostic exercise into an urgent clinical and ethical necessity. By combining vast genetic testing datasets with sophisticated statistical modeling, the Mount Sinai research team has provided a clearer picture of a condition that has historically been obscured by diagnostic gaps, barriers to health insurance, and the limitations of conventional clinical evaluations.<\/p>\n
Understanding Phelan-McDermid Syndrome and Its Genetic Roots<\/p>\n
Phelan-McDermid syndrome is a genetic condition triggered by a deletion or mutation involving the SHANK3 gene, located on the long arm of chromosome 22 (22q13.3 deletion). The SHANK3 gene plays a foundational role in human neurobiology, encoding a master scaffolding protein localized at the postsynaptic density of excitatory synapses. This protein is essential for proper structural organization, synaptic transmission, and communication between neurons. When the gene is mutated or deleted, the architecture of neural circuits is compromised, leading to a cascade of medical, intellectual, and behavioral challenges.<\/p>\n
Clinically, PMS manifests as a broad spectrum of severity. Affected individuals frequently experience global developmental delay, severe speech impairments, hypotonia (low muscle tone), motor dysfunctions, and intellectual disability. Furthermore, a vast majority of individuals diagnosed with PMS also meet the diagnostic criteria for autism spectrum disorder (ASD). In fact, genetic alterations and loss-of-function mutations affecting the SHANK3 gene are currently believed to account for approximately one percent of all autism spectrum disorder cases worldwide. <\/p>\n
Despite these clear clinical markers, many patients remain undiagnosed or misdiagnosed for years, categorized broadly under general developmental delays or idiopathic autism without uncovering the underlying genetic etiology.<\/p>\n
Unprecedented Scale: Mining Genetic Datasets to Reveal the True Prevalence<\/p>\n
To arrive at their revised prevalence estimate of 13.7 cases per 100,000 people\u2014equaling roughly 1 in 7,300 individuals\u2014the research team at Mount Sinai undertook a massive data-aggregation effort. Recognizing that traditional epidemiological methods often fail to capture rare genetic disorders due to underreporting, the investigators bypassed standard patient surveys and instead turned directly to raw genetic testing data.<\/p>\n
The team collaborated closely with major commercial genetic testing laboratories, academic medical centers, and prominent autism research cohorts. By pooling resources, the researchers analyzed genetic records from nearly 180,000 individuals with autism spectrum disorder who had undergone comprehensive genetic testing. <\/p>\n
The analysis synthesized data drawn from ten distinct and robust sources. These included commercial laboratories such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale academic research initiatives like the SPARK (Simons Foundation Powering Autism Research for Knowledge) study and the Autism Sequencing Consortium. Data from several major children’s hospitals across the country were also integrated into the analytical model.<\/p>\n
By meticulously accounting for variables such as undiagnosed cases in the broader population, technological limits inherent in certain types of genetic testing, and instances of Phelan-McDermid syndrome where individuals do not meet the diagnostic thresholds for autism spectrum disorder, the researchers established their benchmark prevalence rate. When extrapolated to the broader United States population, this metric indicates that upwards of 45,000 Americans may be living with PMS\u2014a number vastly exceeding prior historical estimates.<\/p>\n
The Diagnostic Bottleneck: Why Thousands Go Unnoticed<\/p>\n
The stark discrepancy between historical case counts and the new epidemiological reality underscores persistent systemic hurdles in modern healthcare. According to the study’s first author, Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and a certified genetic counselor at the Seaver Autism Center, multiple barriers prevent families from securing a timely diagnosis.<\/p>\n
"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," explains Levy. "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."<\/p>\n
In many clinical settings, initial evaluations for developmental delays focus strictly on behavioral observations rather than molecular genetics. Even when genetic testing is ordered, standard chromosomal microarray analyses can occasionally miss smaller intragenic deletions or specific point mutations within the SHANK3 gene unless targeted sequencing panels or whole-exome sequencing are utilized. Furthermore, strict pre-authorization criteria imposed by commercial health insurance providers frequently delay or deny coverage for comprehensive genomic profiling, leaving vulnerable patients without answers.<\/p>\n
The Clinical Imperative of Universal Genetic Testing<\/p>\n
In light of these findings, the Mount Sinai researchers are advocating for a paradigm shift in pediatric neurology and developmental medicine. They argue that genomic screening should become a standard, routine component of the diagnostic workup for every child presenting with neurodevelopmental differences.<\/p>\n
"We recommend that every child with autism undergo genetic testing, because knowledge is power," asserts Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the study. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."<\/p>\n
This sentiment is echoed across the rare disease and patient advocacy community. The study was supported and funded in part by CureSHANK and Neuren Pharmaceuticals, highlighting a collaborative model where private industry, academic institutions, and patient advocacy groups unite to solve complex epidemiological challenges.<\/p>\n
"Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," states Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals. "Patients cannot benefit from these advances if they never receive a diagnosis."<\/p>\n
A Critical Turning Point: Precision Medicine Enters Clinical Trials<\/p>\n
The publication of this prevalence study coincides with a pivotal era of therapeutic development for Phelan-McDermid syndrome. For decades, clinical management of PMS was strictly palliative and symptomatic, focusing on physical therapy, speech therapy, behavioral interventions, and the management of associated medical complications such as seizures and gastrointestinal distress.<\/p>\n
Today, however, several clinical trials are actively underway, exploring precision-medicine interventions designed to address the root biological mechanisms of the disorder. By targeting the synaptic dysfunction caused by deficient SHANK3 signaling, these novel therapeutics aim to modify the underlying disease trajectory rather than merely managing outward symptoms.<\/p>\n
For patients and their families, obtaining a definitive genetic diagnosis has evolved far beyond an academic exercise. A confirmed case of PMS grants immediate entry into specialized medical surveillance protocols, connects families with dedicated patient support networks, and\u2014most importantly\u2014provides eligibility for life-changing clinical trials and emerging disease-modifying therapies.<\/p>\n
Geraldine Bliss, Board Chair of CureSHANK, emphasized the profound emotional and practical weight of the new data for families navigating the diagnostic odyssey. <\/p>\n
"This study confirms what many families, clinicians, and advocates have suspected for years," Bliss noted. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been important."<\/p>\n
Broader Implications: The "Think Genetic First" Movement<\/p>\n
The release of the Mount Sinai study reinforces ongoing public health initiatives aimed at transforming how clinicians approach developmental disorders. CureSHANK, alongside international partners and medical societies, continues to champion global awareness campaigns\u2014such as the Start Genetic initiative\u2014which encourage physicians, healthcare providers, families, and advocacy organizations to prioritize genetic testing from the earliest signs of neurodevelopmental divergence.<\/p>\n
As medical science marches further into the age of precision medicine, the overarching message of the Mount Sinai research is clear: therapeutic breakthroughs hold little value if the patients who need them remain hidden. By exposing the true scale of Phelan-McDermid syndrome, this landmark study provides the empirical foundation necessary to overhaul screening policies, accelerate clinical trials, and ultimately bring life-altering treatments out of the laboratory and into the hands of the thousands of families waiting for an answer.<\/p>\n","protected":false},"excerpt":{"rendered":"
New research spearheaded by geneticists and clinicians at the Seaver Autism Center for Research and Treatment at Mount Sinai has fundamentally shifted our understanding of Phelan-McDermid syndrome (PMS), a rare and complex genetic disorder. Published in the peer-reviewed journal Autism Research, the landmark study estimates that the condition affects approximately 1 in every 7,300 individuals. …<\/p>\n","protected":false},"author":1,"featured_media":8029,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[145],"tags":[5634,5218,146,882,869,5631,148,4243,5630,5682,5633,1127,2211,5683,1651,5632,147],"class_list":["post-8030","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-wellness","tag-believed","tag-common","tag-health","tag-hidden","tag-landmark","tag-mcdermid","tag-medicine","tag-mount","tag-phelan","tag-plain","tag-previously","tag-reveals","tag-sight","tag-sinai","tag-study","tag-syndrome","tag-wellness"],"_links":{"self":[{"href":"https:\/\/propernews.co\/index.php?rest_route=\/wp\/v2\/posts\/8030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/propernews.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/propernews.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/propernews.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/propernews.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8030"}],"version-history":[{"count":0,"href":"https:\/\/propernews.co\/index.php?rest_route=\/wp\/v2\/posts\/8030\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/propernews.co\/index.php?rest_route=\/wp\/v2\/media\/8029"}],"wp:attachment":[{"href":"https:\/\/propernews.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/propernews.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/propernews.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}